The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies
- PMID: 19277229
- PMCID: PMC2646444
The importance of eyelid closure and nasolacrimal occlusion following the ocular instillation of topical glaucoma medications, and the need for the universal inclusion of one of these techniques in all patient treatments and clinical studies
Abstract
Purpose: To review the effects of nasolacrimal occlusion (NLO) and eyelid closure (ELC) on the ocular and systemic absorption of topically applied glaucoma medications and emphasize the need for the universal application of these techniques during patient treatment and in clinical studies of topically applied glaucoma medications.
Methods: Following a review of data suggesting great clinical benefit from NLO and ELC, the absence of inclusion of these simple techniques in published studies of topical glaucoma medications is identified. The effect of this oversight on these studies is noted with reference to each of the 5 major groups of glaucoma medications.
Results: A review of the literature suggests that NLO and ELC improve intraocular penetration of topically applied glaucoma medications and discourage systemic absorption. The US Food and Drug Administration and the National Institutes of Health discourage the inclusion of these techniques in studies of the efficacy and toxicity of topically applied glaucoma medications. Consequently, all glaucoma studies reported in the literature lack the inclusion of these techniques for 5 minutes. This omission has major implications for patient informed consent, study protocol consistency, and the value of clinical studies, and directly affects the therapeutic index of glaucoma medications in unpredictable and undesirable ways. The undesirable influence on the therapeutic index of each drug influences the safety and efficacy and has implications for the cost of medical treatments, the reproducibility of clinical study results, and dosing regimens, including those of combination therapy, as reflected in the peer-reviewed literature.
Conclusions: Patients should use NLO or ELC for 5 minutes following eye drop treatment with topically applied glaucoma medications. Furthermore, it is essential that these techniques be included in all clinical studies of topically applied glaucoma medications to ensure the most favorable therapeutic index and its accurate determination. This will also help provide the most consistent, reliable, and reproducible study results.
Similar articles
-
Effects of eyelid closure and nasolacrimal duct occlusion on the systemic absorption of ocular timolol in human subjects.J Ocul Pharmacol. 1986 Fall;2(4):365-9. doi: 10.1089/jop.1986.2.365. J Ocul Pharmacol. 1986. PMID: 3503120 Clinical Trial.
-
New technique to reduce systemic side effects of timolol eye drops: The tissue press method-Cross-over clinical trial.Clin Exp Ophthalmol. 2020 Jan;48(1):24-30. doi: 10.1111/ceo.13642. Epub 2019 Oct 17. Clin Exp Ophthalmol. 2020. PMID: 31525271 Clinical Trial.
-
Barriers to glaucoma drug delivery.J Glaucoma. 2008 Mar;17(2):147-56. doi: 10.1097/IJG.0b013e31814b990d. J Glaucoma. 2008. PMID: 18344762 Review.
-
Impact of eyelid closure on the intraocular pressure lowering effect of prostaglandins: a randomised controlled trial.Br J Ophthalmol. 2012 Feb;96(2):250-3. doi: 10.1136/bjo.2010.198887. Epub 2011 Apr 21. Br J Ophthalmol. 2012. PMID: 21515561 Clinical Trial.
-
The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review.Curr Opin Ophthalmol. 2007 Mar;18(2):134-9. doi: 10.1097/ICU.0b013e328089f1c8. Curr Opin Ophthalmol. 2007. PMID: 17301615 Review.
Cited by
-
Brimonidine Eye Drops Causing Encephalopathy in a Patient With Advanced Chronic Kidney Disease.Cureus. 2021 Sep 5;13(9):e17725. doi: 10.7759/cureus.17725. eCollection 2021 Sep. Cureus. 2021. PMID: 34659939 Free PMC article.
-
Subjective and objective assessment of the eye drop instillation technique: A hospital-based cross-sectional study.Indian J Ophthalmol. 2021 Oct;69(10):2638-2642. doi: 10.4103/ijo.IJO_3333_20. Indian J Ophthalmol. 2021. PMID: 34571604 Free PMC article.
-
Considerations of prescribers and pharmacists for the use of non-selective β-blockers in asthma and COPD patients: An explorative study.J Eval Clin Pract. 2018 Apr;24(2):396-402. doi: 10.1111/jep.12869. Epub 2018 Jan 10. J Eval Clin Pract. 2018. PMID: 29319215 Free PMC article.
-
Systemic side effects of eye drops: a pharmacokinetic perspective.Clin Ophthalmol. 2016 Dec 7;10:2433-2441. doi: 10.2147/OPTH.S118409. eCollection 2016. Clin Ophthalmol. 2016. PMID: 27994437 Free PMC article. Review.
-
Principles of pharmacology in the eye.Br J Pharmacol. 2017 Dec;174(23):4205-4223. doi: 10.1111/bph.14024. Epub 2017 Oct 10. Br J Pharmacol. 2017. PMID: 28865239 Free PMC article. Review.
References
-
- Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: Objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533–540. - PubMed
-
- Jampel HD, Okeke CO, Quigley HA, Friedman DS. Poster presentation, American Glaucoma Society; Washington, D.C.: Mar 7, 2008. Patient Use of Topical Therapy.
-
- Kass MA, Meltzer DW, Gordon M, et al. Compliance with topical pilocarpine treatment. Am J Ophthalmol. 1986;101:515–523. - PubMed
-
- Zimmerman TJ, Kooner KS, Kandarakis AS, Ziegler LP. Improving the therapeutic index of topically applied ocular drugs. Arch Ophthalmol. 1984;102:551–553. - PubMed
-
- Zimmerman TJ, Baumann JD, Hetherington J. Side effects of timolol. Surv Ophthalmol. 1983;28:243–249. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical